Enacademic πŸŽ“Analogindex
49 subscribers
77.3K photos
5 videos
249K links
Download Telegram
She likes watching the swirly toilet water, not even hiding the flusher can stop her

submitted by /u/Jordens21 to r/aww link comments
Read more...
*AMD slides as muted outlook clouds Q3 earnings beat with AI chip launch in focus*

Advanced Micro Devices AMD shares slumped lower in pre-market trading after the chipmaker posted mixed third quarter earnings and a muted near-term outlook while hyping the potential for its new AI chips heading into 2024. AMD said non-GAAP earnings for the three months ending in September came in at 70 cents per share, a 4.5% bump from the same period last year that topped Street forecasts by around 2 cents per share. Group revenues, AMD said, rose 4% to $5.8 billion, just ahead of analysts' forecasts of a $5.7 billion tally. Gaming sector revenue was down 8% from last year to $1.5 billion, while data center was flat at $1.6 billion. The client segment, which includes personal computing, saw a 42% revenue gain to $1.5 billion while embedded segment revenues fell 5% to $1.2 billion. Looking into the final months of the, AMD said it sees fourth quarter revenue in the region of $6.1 billion, plus or minus $300 million, with gross margins of around 51.5%. LSEG forecasts had the third quarter revenue forecast at $6.4 billion. AMD's new MI300X chip, however, is likely to draw around $400 million in fourth quarter sales as it looks to challenge Nvidia's NVDA AI-market dominance, while the broader family of MI300 semis are expected to see sales of more than $2 billion over the whole of 2024. The group will host a launch event for the MI300X on December 6. "Multiple large hyperscale customers committed to deploy Instinct MI300 accelerators, supported by our latest ROCm software suite and the growing adoption of an open hardware-agnostic software ecosystem," CEO Lisa Su told investors on a conference call late Tuesday. "Based on the rapid progress we are making with our AI road map execution and purchase commitments from cloud customers, we now expect Data Center GPU revenue to be approximately $400 million in the fourth quarter and exceed $2 billion in 2024 as revenue ramps throughout the year," she added. "This growth would make MI300 the fastest product to ramp to $1 billion in sales in AMD history." AMD shares were marked 2.42% lower in pre-market trading to indicate an opening bell price of $96.12 each, a move that would trim the stock's six-month gain to around 7.2%. We're most encouraged by the data center results and outlook for both server CPU and GPU but are lowering estimates to reflect weak embedded/gaming," said KeyBanc Capital Markets analyst John Vinh, who lowered his price target by $20, to $140 per share, following last night's earnings. "We remain Overweight and see the Dec. 6 launch event for MI300X as the next catalyst," he added.
[Read more...](https://www.thestreet.com/investing/stocks/amd-slides-as-muted-outlook-clouds-q3-earnings-beat-with-ai-chip-launch-in-focus)
AMD slides as muted outlook clouds Q3 earnings beat with AI chip launch in focus

Advanced Micro Devices AMD shares slumped lower in pre-market trading after the chipmaker posted mixed third quarter earnings and a muted near-term outlook while hyping the potential for its new AI chips heading into 2024. AMD said non-GAAP earnings for the three months ending in September came in at 70 cents per share, a 4.5% bump from the same period last year that topped Street forecasts by around 2 cents per share. Group revenues, AMD said, rose 4% to $5.8 billion, just ahead of analysts' forecasts of a $5.7 billion tally. Gaming sector revenue was down 8% from last year to $1.5 billion, while data center was flat at $1.6 billion. The client segment, which includes personal computing, saw a 42% revenue gain to $1.5 billion while embedded segment revenues fell 5% to $1.2 billion. Looking into the final months of the, AMD said it sees fourth quarter revenue in the region of $6.1 billion, plus or minus $300 million, with gross margins of around 51.5%. LSEG forecasts had the third quarter revenue forecast at $6.4 billion. AMD's new MI300X chip, however, is likely to draw around $400 million in fourth quarter sales as it looks to challenge Nvidia's NVDA AI-market dominance, while the broader family of MI300 semis are expected to see sales of more than $2 billion over the whole of 2024. The group will host a launch event for the MI300X on December 6. "Multiple large hyperscale customers committed to deploy Instinct MI300 accelerators, supported by our latest ROCm software suite and the growing adoption of an open hardware-agnostic software ecosystem," CEO Lisa Su told investors on a conference call late Tuesday. "Based on the rapid progress we are making with our AI road map execution and purchase commitments from cloud customers, we now expect Data Center GPU revenue to be approximately $400 million in the fourth quarter and exceed $2 billion in 2024 as revenue ramps throughout the year," she added. "This growth would make MI300 the fastest product to ramp to $1 billion in sales in AMD history." AMD shares were marked 2.42% lower in pre-market trading to indicate an opening bell price of $96.12 each, a move that would trim the stock's six-month gain to around 7.2%. We're most encouraged by the data center results and outlook for both server CPU and GPU but are lowering estimates to reflect weak embedded/gaming," said KeyBanc Capital Markets analyst John Vinh, who lowered his price target by $20, to $140 per share, following last night's earnings. "We remain Overweight and see the Dec. 6 launch event for MI300X as the next catalyst," he added.
Read more...
*CVS Health earnings top forecasts on pharmacy, health care benefits strength*

CVS Health CVS posted stronger-than-expected third quarter earnings Wednesday, powered by gains in its pharmacy and health care benefits division, but stuck to its full-year profit forecasts. CVS said adjusted earnings for the three months ended in September were pegged at $2.21 per share, a 1.8% increase from the same period last year that topped Wall Street's $2.13 per share forecast. Group revenues, CVS said, rose 10.6% from last year to $89.8 billion, again topping analysts' estimates of an $88.25 billion tally. Pharmacy & Consumer sales, which were formerly reported in the Retail segment, were up 6% to $28.87 billion, "driven increased prescription volume and brand inflation,' CVS said. Health Care Benefits revenues were up 16.9% to $26.3 billion. Looking into the final months of the year, CVS repeated that it saw adjusted profits in the region of $8.50 to $8.70 per share and reiterated its forecast for cash flows from its overall business to come in between $12.5 billion to $13.5 billion. "Our colleagues helped us deliver another quarter of positive results across our business areas," said CEO Karen Lynch. "Despite a challenging business environment, we continue adapting to the changing needs of our consumers by connecting our care delivery capabilities in communities across the country, broadening access to care and lowering costs." CVS Health shares were marked 0.85% higher in pre-market trading immediately following the earnings release to indicate an opening bell price of $69.60 each.Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
[Read more...](https://www.thestreet.com/investing/stocks/cvs-earnings-top-forecasts-on-pharmacy-health-care-benefits-strength)
CVS Health earnings top forecasts on pharmacy, health care benefits strength

CVS Health CVS posted stronger-than-expected third quarter earnings Wednesday, powered by gains in its pharmacy and health care benefits division, but stuck to its full-year profit forecasts. CVS said adjusted earnings for the three months ended in September were pegged at $2.21 per share, a 1.8% increase from the same period last year that topped Wall Street's $2.13 per share forecast. Group revenues, CVS said, rose 10.6% from last year to $89.8 billion, again topping analysts' estimates of an $88.25 billion tally. Pharmacy & Consumer sales, which were formerly reported in the Retail segment, were up 6% to $28.87 billion, "driven increased prescription volume and brand inflation,' CVS said. Health Care Benefits revenues were up 16.9% to $26.3 billion. Looking into the final months of the year, CVS repeated that it saw adjusted profits in the region of $8.50 to $8.70 per share and reiterated its forecast for cash flows from its overall business to come in between $12.5 billion to $13.5 billion. "Our colleagues helped us deliver another quarter of positive results across our business areas," said CEO Karen Lynch. "Despite a challenging business environment, we continue adapting to the changing needs of our consumers by connecting our care delivery capabilities in communities across the country, broadening access to care and lowering costs." CVS Health shares were marked 0.85% higher in pre-market trading immediately following the earnings release to indicate an opening bell price of $69.60 each.Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
Read more...
*Π§Ρ‚ΠΎ Ρ‚Π°ΠΊΠΎΠ΅ конструктивная ΠΊΡ€ΠΈΡ‚ΠΈΠΊΠ° ΠΈ ΠΊΠ°ΠΊ Π΅ΠΉ Π½Π°ΡƒΡ‡ΠΈΡ‚ΡŒΡΡ*

ΠžΡ‚Π²Π΅Ρ‡Π°Π΅Ρ‚ HR-ΠΊΠΎΠ½ΡΡƒΠ»ΡŒΡ‚Π°Π½Ρ‚.
[Read more...](https://burninghut.ru/konstruktivnaya-kritika/?utm_source=lifehacker.ru&utm_medium=referral&utm_campaign=teaser&utm_content=konstruktivnaya-kritika)
*Π£Ρ‡Ρ‘Π½Ρ‹Π΅ подсчитали, ΠΊΠΎΠ³Π΄Π° глобальноС ΠΏΠΎΡ‚Π΅ΠΏΠ»Π΅Π½ΠΈΠ΅ достигнСт критичСской ΠΎΡ‚ΠΌΠ΅Ρ‚ΠΊΠΈ*

Π’Ρ€Π΅ΠΌΠ΅Π½ΠΈ ΠΎΡΡ‚Π°Π»ΠΎΡΡŒ ΠΎΡ‡Π΅Π½ΡŒ ΠΌΠ°Π»ΠΎ.
[Read more...](https://lifehacker.ru/bezopasnyj-porog-globalnogo-potepleniya/)